Core Insights - The article discusses the introduction of Daridorexant, a new generation insomnia medication, at the 2025 China International Import Expo, highlighting its potential to reshape the insomnia treatment landscape in China, where nearly half of adults experience sleep issues [3][20]. Industry Overview - The insomnia treatment market in China is significant, with the sleep economy exceeding 300 billion yuan and showing steady growth, indicating further expansion potential as awareness of sleep quality increases [16]. - Traditional insomnia medications have limitations, including dependency and residual effects, leading to a demand for more precise and natural treatment options [5][6]. Product Introduction - Daridorexant, developed by Swiss company Idorsia, is a dual orexin receptor antagonist (DORA) that targets the underlying physiological mechanisms of insomnia, distinguishing it from traditional sedatives [8][11]. - The drug has a half-life of approximately 8 hours, allowing for a full night's sleep without next-day drowsiness, aligning with modern lifestyle demands [11][17]. Clinical Data - Clinical studies published in The Lancet Neurology demonstrate that Daridorexant significantly improves sleep onset and maintenance compared to placebo, extending total sleep time without altering sleep structure or causing dependency [13][14]. - In China, the drug's phase III clinical trial showed consistent efficacy and safety results, reducing sleep onset time by 35 minutes and nighttime awakenings by 30 minutes, while also improving daytime functioning [14]. Competitive Advantages - Daridorexant's mechanism directly addresses insomnia's pathophysiology, presenting a safety profile with low dependency risk, making it more appealing for prescriptions [17]. - The drug is not classified as a controlled substance, simplifying prescription processes and enhancing accessibility for patients [17]. Local Production and Accessibility - Local production of Daridorexant is expected to reduce costs and improve patient accessibility, with plans for production in Hainan, China, anticipated to meet the needs of insomnia patients effectively [18][19]. - The local manufacturing strategy aims to ensure stable supply chains and lower drug prices, which are critical for chronic disease management [19]. Treatment Paradigm Shift - The introduction of Daridorexant signifies a shift in insomnia treatment from forced sleep to promoting natural sleep, focusing on overall sleep health management rather than merely symptom control [20].

Core Insights - The article discusses the introduction of Daliresp, a new generation insomnia treatment, at the 2025 China International Import Expo, highlighting its potential to reshape the insomnia treatment landscape in China, where nearly 48.5% of adults experience sleep issues [1][6]. Group 1: Traditional Insomnia Treatments - Traditional insomnia medications often lead to dependency and residual effects, causing patients to face a dilemma between sleeplessness and poor next-day performance [2][4]. - Long-term use of conventional sedatives can result in tolerance, requiring higher doses for the same effect, and about 30% of users may experience withdrawal symptoms upon cessation [2][4]. Group 2: Mechanism of Daliresp - Daliresp operates as a dual orexin receptor antagonist (DORA), targeting the orexin system that regulates wakefulness and sleep, thus promoting natural sleep without broadly suppressing brain activity [3][4]. - Clinical studies have shown that Daliresp significantly improves sleep onset and maintenance while not altering sleep structure, which distinguishes it from traditional sedatives [4][5]. Group 3: Clinical Data and Efficacy - In clinical trials, Daliresp reduced sleep onset time by 35 minutes and wake time after sleep onset by 30 minutes, extending total sleep time by one hour without increasing next-day drowsiness [5]. - The drug has shown consistency in effectiveness and safety in both Chinese and overseas clinical studies, with no evidence of dependency or rebound insomnia [5]. Group 4: Market Potential and Competitive Advantages - The Chinese sleep health market exceeds 300 billion yuan and continues to grow, presenting a significant opportunity for Daliresp to capture market share due to its unique mechanism and clinical advantages [6][7]. - Daliresp's safety profile, low dependency risk, and alignment with normal sleep cycles make it appealing to both doctors and patients, enhancing treatment adherence [6][7]. Group 5: Local Production and Accessibility - Local production of Daliresp is expected to reduce costs and improve patient accessibility, addressing the challenges of high prices and supply chain uncertainties associated with imported drugs [8][9]. - The production facility in Hainan is set to achieve an annual capacity of 600 million tablets, ensuring a stable supply for insomnia patients [9]. Group 6: Transformation in Insomnia Treatment - The introduction of Daliresp signifies a shift in insomnia treatment from forced sleep to natural sleep, emphasizing overall sleep health management rather than just symptom control [10]. - As awareness of sleep health increases, medications like Daliresp that target specific physiological mechanisms will play a crucial role in this evolving treatment paradigm [10].